Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation

Song,Jing; Tang,Yongyao; Song,Fangzhou

doi:10.3892/ijo.2023.5559

Lnc‑RGS5 sponges miR‑542‑5p to promote FoxM1/VEGFA signaling and breast cancer cell proliferation

Authors:
- Jing Song
- Yongyao Tang
- Fangzhou Song
View Affiliations

Affiliations: Molecular and Tumor Research Center, The Basic Medical School of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: August 10, 2023 https://doi.org/10.3892/ijo.2023.5559
Article Number: 111
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BRCA) exhibits a high incidence rate among women worldwide. LOC127814295 (ENSG00000232995), termed long non‑coding (lnc)‑regulator of G protein signaling 5 (RGS5), is a novel lncRNA with a genomic region overlapping with protein‑coding gene RGS5. Results obtained using The Cancer Genome Atlas demonstrated that lnc‑RGS5 was deregulated in diverse cancer types, including BRCA; however, the functional role of lnc‑RGS5 remains unclear. Results of the present study demonstrated that lnc‑RGS5 was upregulated in BRCA tissues compared with healthy samples (n=30; P<0.0001), and was associated with the overall survival of patients with triple‑negative BRCA (n=106; P<0.05). Moreover, lnc‑RGS5 expression was significantly higher in triple‑negative BRCA samples than in LumA, LumB, or Her2 subtypes (P<0.05). Functionally, lnc‑RGS5 upregulation promoted BRCA cell proliferation in vitro, whereas lnc‑RGS5 knockdown elicited the opposite function. Stable knockdown of lnc‑RGS5 inhibited tumor cell proliferation in vivo. Bioinformatics analysis revealed that lnc‑RGS5 was significantly associated with RNA binding involved in post‑transcriptional gene silencing (P=0.002). Mechanistically, lnc‑RGS5 functions as a competing endogenous RNA via competitively sponging miR‑542‑5p to upregulate forkhead box M1 (FoxM1) and the VEGFA/Neuropilin 1 axis; thus, promoting BRCA cell proliferation in vitro. Moreover, rescue experiments validated that the lnc‑RGS5/miR‑542‑5p/FoxM1 axis promoted BRCA cell growth in vivo. Collectively, results of the present study demonstrated that lnc‑RGS5 may exhibit potential as a novel oncogenic lncRNA in BRCA. The present study may provide a novel theoretical basis for the role of lncRNA in the targeted therapy of BRCA.

View Figures

View References

1	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI
2	Denkert C, Liedtke C, Tutt A and von Minckwitz G: Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 389:2430–2442. 2017. View Article : Google Scholar
3	Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S and Chen Y: Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 15:1212022. View Article : Google Scholar :
4	Murphy CG: The Role of CDK4/6 inhibitors in breast cancer. Curr Treat Options Oncol. 20:522019. View Article : Google Scholar
5	Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T and Navin NE: Chemoresistance Evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 173:879–893.e13. 2018. View Article : Google Scholar : PubMed/NCBI
6	Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, Tang-Tan AM, Guye ML, Chang DZ, Winston JS, et al: Perspectives on triple-negative breast cancer: Current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel). 12:23922020. View Article : Google Scholar : PubMed/NCBI
7	Mahdi A, Darvishi B, Majidzadeh AK, Salehi M and Farahmand L: Challenges facing antiangiogenesis therapy: The significant role of hypoxia-inducible factor and MET in development of resistance to anti-vascular endothelial growth factor-targeted therapies. J Cell Physiol. 234:5655–5663. 2019. View Article : Google Scholar
8	Wang J, Xie S, Yang J, Xiong H, Jia Y, Zhou Y, Chen Y, Ying X, Chen C, Ye C, et al: The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 12:812019. View Article : Google Scholar : PubMed/NCBI
9	Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q, Qin Q, Zhao L, Huang Q, Luo Z, et al: Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 37:2892018. View Article : Google Scholar :
10	Shahi P, Wang CY, Chou J, Hagerling C, Gonzalez Velozo H, Ruderisch A, Yu Y, Lai MD and Werb Z: GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. Oncogene. 36:5567–5575. 2017. View Article : Google Scholar
11	Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z and Wang J: LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 53:e128552020. View Article : Google Scholar : PubMed/NCBI
12	Dasgupta S, Ghosh T, Dhar J, Bhuniya A, Nandi P, Das A, Saha A, Das J, Guha I, Banerjee S, et al: RGS5-TGFβ-Smad2/3 axis switches proto anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. Cell Death Differ. 28:3052–3076. 2021. View Article : Google Scholar :
13	Silini A, Ghilardi C, Figini S, Sangalli F, Fruscio R, Dahse R, Pedley RB, Giavazzi R and Bani M: Regulator of G-protein signaling 5 (RGS5) protein: A novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci. 69:1167–1178. 2012. View Article : Google Scholar
14	Boss CN, Grünebach F, Brauer K, Häntschel M, Mirakaj V, Weinschenk T, Stevanovic S, Rammensee HG and Brossart P: Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res. 13:3347–3355. 2007. View Article : Google Scholar
15	Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
16	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
17	Krüger J and Rehmsmeier M: RNAhybrid: MicroRNA target prediction easy, fast and flexible. Nucleic Acids Res. 34(Web Server Issue): W451–W454. 2006. View Article : Google Scholar : PubMed/NCBI
18	Enright AJ, John B, Gaul U, Tuschl T, Sander C and Marks DS: MicroRNA targets in Drosophila. Genome Biol. 5:R12003. View Article : Google Scholar
19	Yevshin I, Sharipov R, Valeev T, Kel A and Kolpakov F: GTRD: A database of transcription factor binding sites identified by ChIP-seq experiments. Nucleic Acids Res. 45(D1): D61–D67. 2017. View Article : Google Scholar :
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
21	Wang S, Zhen L, Liu Z, Ai Q, Ji Y, Du G, Wang Y and Bu Y: Identification and analysis of the promoter region of the human HAS3 gene. Biochem Biophys Res Commun. 460:1008–1014. 2015. View Article : Google Scholar : PubMed/NCBI
22	Tian Y, Ma R, Sun Y, Liu H, Zhang H, Sun Y, Liu L, Li Y, Song L and Gao P: SP1-activated long noncoding RNA lncRNA GCMA functions as a competing endogenous RNA to promote tumor metastasis by sponging miR-124 and miR-34a in gastric cancer. Oncogene. 39:4854–4868. 2020. View Article : Google Scholar : PubMed/NCBI
23	Yang C, Chen H, Yu L, Shan L, Xie L, Hu J, Chen T and Tan Y: Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer. Cancer Gene Ther. 20:117–124. 2013. View Article : Google Scholar : PubMed/NCBI
24	Luo M, Hou L, Li J, Shao S, Huang S, Meng D, Liu L, Feng L, Xia P, Qin T and Zhao X: VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin. Cancer Lett. 373:1–11. 2016. View Article : Google Scholar : PubMed/NCBI
25	Yao S, Fan LYN and Lam EWF: The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin Cancer Biol. 50:77–89. 2018. View Article : Google Scholar
26	Kalathil D, John S and Nair AS: FOXM1 and cancer: Faulty cellular signaling derails homeostasis. Front Oncol. 10:6268362021. View Article : Google Scholar : PubMed/NCBI
27	Peng WX, Han X, Zhang CL, Ge L, Du FY, Jin J and Gong AH: FoxM1-mediated RFC5 expression promotes temozolomide resistance. Cell Biol Toxicol. 33:527–537. 2017. View Article : Google Scholar : PubMed/NCBI
28	Bushweller JH: Targeting transcription factors in cancer-from undruggable to reality. Nat Rev Cancer. 19:611–624. 2019. View Article : Google Scholar : PubMed/NCBI
29	Wang SH, Ma F, Tang ZH, Wu XC, Cai Q, Zhang MD, Weng MZ, Zhou D, Wang JD and Quan ZW: Long non-coding RNA H19 regulates FOXM1 expression by competitively binding endogenous miR-342-3p in gallbladder cancer. J Exp Clin Cancer Res. 35:1602016. View Article : Google Scholar : PubMed/NCBI
30	Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D and Mukhopadhyay D: VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
31	Simons M, Gordon E and Claesson-Welsh L: Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 17:611–625. 2016. View Article : Google Scholar : PubMed/NCBI
32	Cheng S, Zhang Z, Hu C, Xing N, Xia Y and Pang B: Pristimerin suppressed breast cancer progression via miR-542-5p/DUB3 axis. Onco Targets Ther. 13:6651–6660. 2020. View Article : Google Scholar : PubMed/NCBI
33	He RQ, Li XJ, Liang L, Xie Y, Luo DZ, Ma J, Peng ZG, Hu XH and Chen G: The suppressive role of miR-542-5p in NSCLC: The evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model. BMC Cancer. 17:6552017. View Article : Google Scholar : PubMed/NCBI